

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

Information for the public

Published: 28 June 2017

www.nice.org.uk

Blinatumomab (Blincyto) is available on the NHS as a possible treatment for adults with acute lymphoblastic leukaemia when:

- the leukaemia is precursor B-cell and Philadelphia-chromosome-negative
- other treatments haven't worked or the leukaemia has come back.

If you are not eligible for treatment, you should be able to continue taking blinatumomab until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Macmillan Cancer Support](#), 0808 808 0000
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0207 504 2200
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [Leukaemia Cancer Society](#), 0208 374 4821
- [Leukaemia CARE](#), 08088 010 444

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2559-9